These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28588796)

  • 1. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
    Usami E; Kimura M; Iwai M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2017 Jun; 6(6):955-959. PubMed ID: 28588796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
    Philips A; Radhakrishnan V; Ganesan P; Ganesan TS; Ramamurthy J; Dhanushkodi M; Sagar TG
    Indian J Hematol Blood Transfus; 2018 Oct; 34(4):618-622. PubMed ID: 30369730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
    Takai M; Yamauchi T; Matsuda Y; Tai K; Ikegaya S; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2015 May; 9(5):2119-2125. PubMed ID: 26137024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
    Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
    Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
    Chiang J; Chan A; Lian T; Tay K; Quek R; Tao M; Lim ST
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):351-6. PubMed ID: 22151984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of Anaphylaxis during Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database.
    Kobayashi S; Yasu T; Akazawa M
    Curr Oncol; 2022 Dec; 29(12):9826-9832. PubMed ID: 36547186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.